Economic Burden of Acute Myeloid Leukemia in European Union: Results from a Systematic Review of Literature.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a heterogenous malignancy whose management is associated with considerable healthcare resource utilization and high expenditures because of recurrent and extended hospitalizations, multiple outpatient visits, and a wide range of supportive care. Modern therapies with improved safety profiles may assist in reducing healthcare costs; however, they are usually more expensive than standard chemotherapies. Few studies have addressed the expenses and burden of AML. Most of these studies were conducted in the USA. Very little research is available from the European Union (EU).

Objectives

The aim of this study was to assess the economic impact of AML and determine the major cost-driving factors for its treatment in the EU.

Methods

Th

SUBMITTER: Saeed A 

PROVIDER: S-EPMC12037953 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature